...
首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1.
【24h】

Dominant epitopes and allergic cross-reactivity: complex formation between a Fab fragment of a monoclonal murine IgG antibody and the major allergen from birch pollen Bet v 1.

机译:显性表位和过敏性交叉反应性:单克隆鼠类IgG抗体的Fab片段与桦木花粉Bet v 1的主要过敏原之间的复合物形成。

获取原文
获取原文并翻译 | 示例
           

摘要

The symptoms characteristic of allergic hypersensitivity are caused by the release of mediators, i.e., histamine, from effector cells such as basophils and mast cells. Allergens with more than one B cell epitope cross-link IgE Abs bound to high affinity FcepsilonRI receptors on mast cell surfaces leading to aggregation and subsequent mediator release. Thus, allergen-Ab complexes play a crucial role in the cascade leading to the allergic response. We here report the structure of a 1:1 complex between the major birch pollen allergen Bet v 1 and the Fab fragment from a murine monoclonal IgG1 Ab, BV16, that has been solved to 2.9 A resolution by x-ray diffraction. The mAb is shown to inhibit the binding of allergic patients' IgE to Bet v 1, and the allergen-IgG complex may therefore serve as a model for the study of allergen-IgE interactions relevant in allergy. The size of the BV16 epitope is 931 A2 as defined by the Bet v 1 Ab interaction surface. Molecular interactions predicted to occur in the interface are likewise in agreement with earlier observations on Ag-Ab complexes. The epitope is formed by amino acids that are conserved among major allergens from related species within the Fagales order. In combination with a surprisingly high inhibitory capacity of BV16 with respect to allergic patients' serum IgE binding to Bet v 1, these observations provide experimental support for the proposal of dominant IgE epitopes located in the conserved surface areas. This model will facilitate the development of new and safer vaccines for allergen immunotherapy in the form of mutated allergens.
机译:过敏性超敏反应的特征性症状是由诸如嗜碱性粒细胞和肥大细胞的效应细胞释放介质,即组胺引起的。具有一个以上B细胞表位的过敏原与肥大细胞表面上的高亲和力FcepsilonRI受体结合的IgE Abs交联,导致聚集和随后的介质释放。因此,过敏原-Ab复合物在导致过敏反应的级联反应中起着至关重要的作用。我们在这里报告了主要的桦树花粉变应原Bet v 1与来自鼠类单克隆IgG1 Ab BV16的Fab片段之间1:1复合物的结构,该结构已通过X射线衍射解析为2.9 A分辨率。已显示mAb抑制过敏患者的IgE与Bet v 1的结合,因此,过敏原IgG复合物可作为研究与过敏相关的过敏原-IgE相互作用的模型。 BV16表位的大小由Bet v 1 Ab相互作用表面定义为931 A2。预计在界面上发生的分子相互作用也与先前对Ag-Ab复合物的观察一致。该表位由Fagales顺序内相关物种的主要过敏原中保守的氨基酸形成。结合BV16对变态反应患者的血清IgE与Bet v 1结合的惊人抑制能力,这些观察结果为位于保守表面积的主要IgE表位的提议提供了实验支持。该模型将以突变的过敏原形式促进开发用于过敏原免疫疗法的新型和更安全的疫苗。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号